2016 Annual Meeting

SC33-Ovarian Carcinoma: An Update On Histotype Diagnosis, Primary Site Assignment, And Staging

Room CC 611-612, March 16 2016, 1:30pm to 5:30pm

Description

SC33-Ovarian Carcinoma: An Update On Histotype Diagnosis, Primary Site Assignment, And Staging

Session Credits: 3 CME and 3 SAMs

Faculty: C. Blake Gilks MD, University of British Columbia, Vancouver BC; M Kobel MD, University of Calgary, Calgary AB; Naveena Singh FRCPath (UK), Barts Health NHS Trust, London UK

This is a practically-oriented course on ovarian epithelial malignancies, and is designed for general surgical pathologists and pathology residents. There have been important recent developments in the pathology of ovarian carcinomas, the most common ovarian malignancy, that impact on routine surgical pathology practice, and these developments are the focus of this course. Accurate diagnosis of ovarian carcinoma histotype is important for treatment and for assessment of genetic risk, and there are immunomarkers available that can serve as aids in histotype diagnosis. There are also recent advances in our understanding of site of origin of these carcinomas that impact on assignment of primary site and stage in our diagnostic pathology reports. Finally, neoadjuvant chemotherapy is increasingly being used, and criteria have been developed (and adopted by the International Collaboration on Cancer Reporting) that allow reproducible and clinically relevant assessment of treatment response. This course will consist of an introduction, on clinical aspects of ovarian carcinoma, followed by a series of case presentations, with virtual slides, illustrating important diagnostic points and pitfalls in ovarian carcinoma histotype differential diagnosis, selection and interpretation of immunostains, assessing response to chemotherapy, and primary site assignment/staging. There will be a brief presentation on quality assurance for immunostains of relevance to ovarian carcinoma histotype diagnosis (e.g. WT1, Napsin A, p53).

We will:

  • Present criteria that allow for accurate and reproducible diagnosis of high-grade serous, low-grade serous, mucinous, endometrioid, clear cell, and mixed ovarian carcinoma.
  • Provide an overview of the clinical importance of accurate diagnosis of ovarian carcinoma histotype
  • Describe how immunostains can be used in selected cases to improve the accuracy of histotype diagnosis, and how optimal staining quality can be achieved with these immunostains in your laboratory
  • Offer practical guidelines for primary site assignment, staging and assessment of response to neoadjuvant chemotherapy in the most common histotype, high-grade serous carcinoma.

Course materials provided online will be virtual slides, a detailed course syllabus, including references and, after the course, access to unstained tissue microarray slides consisting of multiple ovarian carcinoma cases, that will allow them to validate immunostains performed in their laboratories.

Upon completion of this educational activty, participants will be able to:

  1. Accurately diagnosis ovarian carcinoma histotypes, applying immunostains in selected difficult cases as an aid in histotype diagnosis
  2. Consistently assign primary site and stage, and assess response to neoadjuvant chemotherapy in cases of high-grade serous carcinoma.

Meetings

home-circle-inset-1
view more